Basic Study
Copyright ©The Author(s) 2025.
World J Gastrointest Oncol. May 15, 2025; 17(5): 102417
Published online May 15, 2025. doi: 10.4251/wjgo.v17.i5.102417
Figure 5
Figure 5 SNHG5 directly binds to miR-26b in colorectal cancer. A: Quantitative real-time polymerase chain reaction (qRT-PCR) was used to analyze SNHG5 expression in the nuclear and cytoplasmic fractions of LOVO and HT-29 cells; B: A Venn diagram was used to identify potential miRNAs that may target the binding region of SNHG5; C: The expression levels of miR-26b were evaluated via qRT-PCR in LOVO and HT-29 cells transfected with SNHG5 and control or long noncoding RNAs SNHG5 small interfering RNA (siRNA), control siRNA; D: A dual-luciferase assay was used to assess the seed-matching sites or mutation sites between SNHG5 and miR-26b in HEK-293T cells; E: Anti-argonaute 2 RNA immunoprecipitation analyses were performed using LOVO and HT-29 cells transfected with miR-26b, and the enrichment of SNHG5 was analyzed via qRT-PCR. bP < 0.01. Si-NC: Control small interfering RNA; Si-SNHG5: SNHG5 small interfering RNA; WT: Wild type; Mut: Mutant; miR-NC: MiR-control; NS: No significance; CMV: Cytomegalovirus; Ago-2: Argonaute 2.